Yehoda M. Martei

Dr. Yehoda M. Martei serves as Assistant Professor of Medicine in the Hematology-Oncology division at the University of Pennsylvania's Perelman School of Medicine. A Yale University medical graduate with residency training at UCSF and fellowship at Penn, she has established a research program addressing critical challenges at the intersection of oncology, health disparities, and global health.

Her research spans three primary domains: health disparities in cancer care (particularly racial disparities in breast cancer treatment), antimicrobial resistance as a cancer care delivery challenge, and global oncology implementation in Sub-Saharan Africa. Dr. Martei has published extensively in high-impact journals including The Lancet Oncology, JAMA Network Open, and Journal of Clinical Oncology Global Oncology, with numerous 2024-2025 publications reflecting active research programs.

Her work in Botswana examines breast cancer management, hypofractionation adoption, and the complex relationship between HIV and cancer. She has been increasingly vocal about antimicrobial resistance as an emerging crisis in cancer care, publishing both research studies and opinion pieces arguing that drug-resistant infections fundamentally compromise cancer treatment delivery. Dr. Martei's approach combines rigorous clinical research with practical implementation science to address real-world barriers to high-quality cancer care.

Her scientific contributions include:

• Multiple studies on racial disparities in breast cancer care for older adults
• Groundbreaking research on antimicrobial resistance burden in cancer patients
• Systematic reviews of cancer screening implementation in Sub-Saharan Africa
• Analysis of essential medicines in national cancer control plans
• Development of strategies for cardio-oncology trial diversity

Dr. Martei actively engages in knowledge translation through media appearances, including a One Health Trust podcast on 'The Invisible Second Threat to Cancer Patients' and commentary in STAT News emphasizing that 'oncologists need to see antimicrobial resistance as a cancer care delivery crisis.' Her work demonstrates commitment to both scholarly excellence and practical impact in cancer care delivery worldwide.